View Financial HealthZentiva 배당 및 자사주 매입배당 기준 점검 0/6Zentiva 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • Nov 17Third quarter 2024 earnings released: EPS: RON0.085 (vs RON0.074 in 3Q 2023)Third quarter 2024 results: EPS: RON0.085 (up from RON0.074 in 3Q 2023). Revenue: RON273.7m (up 17% from 3Q 2023). Net income: RON59.0m (up 14% from 3Q 2023). Profit margin: 22% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Sep 03Second quarter 2024 earnings released: EPS: RON0.099 (vs RON0.043 in 2Q 2023)Second quarter 2024 results: EPS: RON0.099 (up from RON0.043 in 2Q 2023). Revenue: RON285.0m (up 30% from 2Q 2023). Net income: RON68.9m (up 132% from 2Q 2023). Profit margin: 24% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.분석 기사 • Jul 30Take Care Before Diving Into The Deep End On Zentiva S.A. (BVB:SCD)When close to half the companies in Romania have price-to-earnings ratios (or "P/E's") above 17x, you may consider...Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON4.16, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 56% over the past three years.Reported Earnings • May 19First quarter 2024 earnings released: EPS: RON0.11 (vs RON0.061 in 1Q 2023)First quarter 2024 results: EPS: RON0.11 (up from RON0.061 in 1Q 2023). Revenue: RON266.3m (up 15% from 1Q 2023). Net income: RON74.2m (up 74% from 1Q 2023). Profit margin: 28% (up from 19% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 03Full year 2023 earnings released: EPS: RON0.27 (vs RON0.14 in FY 2022)Full year 2023 results: EPS: RON0.27 (up from RON0.14 in FY 2022). Revenue: RON945.7m (up 25% from FY 2022). Net income: RON191.1m (up 92% from FY 2022). Profit margin: 20% (up from 13% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.분석 기사 • Mar 02Zentiva S.A. (BVB:SCD) Doing What It Can To Lift SharesThere wouldn't be many who think Zentiva S.A.'s ( BVB:SCD ) price-to-earnings (or "P/E") ratio of 11.6x is worth a...New Risk • Nov 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: RON0.074 (vs RON0.003 in 3Q 2022)Third quarter 2023 results: EPS: RON0.074 (up from RON0.003 in 3Q 2022). Revenue: RON233.9m (up 33% from 3Q 2022). Net income: RON51.5m (up RON49.7m from 3Q 2022). Profit margin: 22% (up from 1.0% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Nov 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.78, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Negligible returns to shareholders over past three years.Reported Earnings • Sep 03Second quarter 2023 earnings released: EPS: RON0.043 (vs RON0.038 in 2Q 2022)Second quarter 2023 results: EPS: RON0.043 (up from RON0.038 in 2Q 2022). Revenue: RON219.9m (up 14% from 2Q 2022). Net income: RON29.6m (up 11% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.3% average weekly change).New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).Reported Earnings • May 18First quarter 2023 earnings released: EPS: RON0.061 (vs RON0.007 in 1Q 2022)First quarter 2023 results: EPS: RON0.061 (up from RON0.007 in 1Q 2022). Revenue: RON230.7m (up 36% from 1Q 2022). Net income: RON42.7m (up RON37.8m from 1Q 2022). Profit margin: 19% (up from 2.9% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 31Full year 2022 earnings released: EPS: RON0.14 (vs RON0.15 in FY 2021)Full year 2022 results: EPS: RON0.14 (down from RON0.15 in FY 2021). Revenue: RON759.6m (up 6.9% from FY 2021). Net income: RON99.5m (down 5.9% from FY 2021). Profit margin: 13% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: RON0.003 (vs RON0.02 in 3Q 2021)Third quarter 2022 results: EPS: RON0.003 (down from RON0.02 in 3Q 2021). Revenue: RON175.4m (up 1.5% from 3Q 2021). Net income: RON1.83m (down 87% from 3Q 2021). Profit margin: 1.0% (down from 8.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 06Second quarter 2022 earnings released: EPS: RON0.038 (vs RON0.016 in 2Q 2021)Second quarter 2022 results: EPS: RON0.038 (up from RON0.016 in 2Q 2021). Revenue: RON193.4m (up 16% from 2Q 2021). Net income: RON26.8m (up 145% from 2Q 2021). Profit margin: 14% (up from 6.6% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: RON0.14 (up from RON0.094 in FY 2020). Revenue: RON694.8m (up 25% from FY 2020). Net income: RON94.7m (up 44% from FY 2020). Profit margin: 14% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS RON0.02 (vs RON0.017 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: RON172.7m (up 26% from 3Q 2020). Net income: RON13.8m (up 20% from 3Q 2020). Profit margin: 8.0% (down from 8.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.Reported Earnings • Sep 03Second quarter 2021 earnings released: EPS RON0.016 (vs RON0.011 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: RON167.2m (up 30% from 2Q 2020). Net income: RON11.0m (up 41% from 2Q 2020). Profit margin: 6.6% (up from 6.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Board Change • Jul 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • May 24Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak FoundationsThe recent earnings posted by Zentiva S.A. ( BVB:SCD ) were solid, but the stock didn't move as much as we expected. We...Reported Earnings • May 19First quarter 2021 earnings released: EPS RON0.034 (vs RON0.049 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON163.1m (up 6.5% from 1Q 2020). Net income: RON23.6m (down 31% from 1Q 2020). Profit margin: 14% (down from 22% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 03Full year 2020 earnings released: EPS RON0.088 (vs RON0.082 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: RON602.3m (up 7.7% from FY 2019). Net income: RON61.3m (up 40% from FY 2019). Profit margin: 10% (up from 7.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.분석 기사 • Mar 01Zentiva (BVB:SCD) Has Gifted Shareholders With A Fantastic 201% Total Return On Their InvestmentPassive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can...공시 • Jan 29Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery PlatformsNanologica AB (publ) announced a collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements. The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement. Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees.분석 기사 • Jan 25Zentiva S.A.'s (BVB:SCD) Stock Is Going Strong: Have Financials A Role To Play?Most readers would already be aware that Zentiva's (BVB:SCD) stock increased significantly by 11% over the past three...Is New 90 Day High Low • Jan 14New 90-day high: RON2.98The company is up 6.0% from its price of RON2.82 on 16 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.분석 기사 • Dec 18Zentiva S.A. (BVB:SCD) Investors Are Less Pessimistic Than ExpectedWhen close to half the companies in Romania have price-to-earnings ratios (or "P/E's") below 12x, you may consider...지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SCD 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SCD 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Zentiva 배당 수익률 vs 시장SCD의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SCD)0%시장 하위 25% (RO)1.7%시장 상위 25% (RO)6.2%업계 평균 (Pharmaceuticals)2.7%분석가 예측 (SCD) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SCD 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SCD 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: SCD RO 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: SCD 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YRO 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/02/17 22:26종가2024/11/20 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Zentiva S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: RON0.085 (vs RON0.074 in 3Q 2023)Third quarter 2024 results: EPS: RON0.085 (up from RON0.074 in 3Q 2023). Revenue: RON273.7m (up 17% from 3Q 2023). Net income: RON59.0m (up 14% from 3Q 2023). Profit margin: 22% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Sep 03Second quarter 2024 earnings released: EPS: RON0.099 (vs RON0.043 in 2Q 2023)Second quarter 2024 results: EPS: RON0.099 (up from RON0.043 in 2Q 2023). Revenue: RON285.0m (up 30% from 2Q 2023). Net income: RON68.9m (up 132% from 2Q 2023). Profit margin: 24% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
분석 기사 • Jul 30Take Care Before Diving Into The Deep End On Zentiva S.A. (BVB:SCD)When close to half the companies in Romania have price-to-earnings ratios (or "P/E's") above 17x, you may consider...
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON4.16, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 27x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 56% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: RON0.11 (vs RON0.061 in 1Q 2023)First quarter 2024 results: EPS: RON0.11 (up from RON0.061 in 1Q 2023). Revenue: RON266.3m (up 15% from 1Q 2023). Net income: RON74.2m (up 74% from 1Q 2023). Profit margin: 28% (up from 19% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 03Full year 2023 earnings released: EPS: RON0.27 (vs RON0.14 in FY 2022)Full year 2023 results: EPS: RON0.27 (up from RON0.14 in FY 2022). Revenue: RON945.7m (up 25% from FY 2022). Net income: RON191.1m (up 92% from FY 2022). Profit margin: 20% (up from 13% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
분석 기사 • Mar 02Zentiva S.A. (BVB:SCD) Doing What It Can To Lift SharesThere wouldn't be many who think Zentiva S.A.'s ( BVB:SCD ) price-to-earnings (or "P/E") ratio of 11.6x is worth a...
New Risk • Nov 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 15% per year over the past 5 years. High level of non-cash earnings (23% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change).
Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: RON0.074 (vs RON0.003 in 3Q 2022)Third quarter 2023 results: EPS: RON0.074 (up from RON0.003 in 3Q 2022). Revenue: RON233.9m (up 33% from 3Q 2022). Net income: RON51.5m (up RON49.7m from 3Q 2022). Profit margin: 22% (up from 1.0% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Nov 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.78, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Negligible returns to shareholders over past three years.
Reported Earnings • Sep 03Second quarter 2023 earnings released: EPS: RON0.043 (vs RON0.038 in 2Q 2022)Second quarter 2023 results: EPS: RON0.043 (up from RON0.038 in 2Q 2022). Revenue: RON219.9m (up 14% from 2Q 2022). Net income: RON29.6m (up 11% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.3% average weekly change).
New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.4% average weekly change).
Reported Earnings • May 18First quarter 2023 earnings released: EPS: RON0.061 (vs RON0.007 in 1Q 2022)First quarter 2023 results: EPS: RON0.061 (up from RON0.007 in 1Q 2022). Revenue: RON230.7m (up 36% from 1Q 2022). Net income: RON42.7m (up RON37.8m from 1Q 2022). Profit margin: 19% (up from 2.9% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 31Full year 2022 earnings released: EPS: RON0.14 (vs RON0.15 in FY 2021)Full year 2022 results: EPS: RON0.14 (down from RON0.15 in FY 2021). Revenue: RON759.6m (up 6.9% from FY 2021). Net income: RON99.5m (down 5.9% from FY 2021). Profit margin: 13% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: RON0.003 (vs RON0.02 in 3Q 2021)Third quarter 2022 results: EPS: RON0.003 (down from RON0.02 in 3Q 2021). Revenue: RON175.4m (up 1.5% from 3Q 2021). Net income: RON1.83m (down 87% from 3Q 2021). Profit margin: 1.0% (down from 8.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 06Second quarter 2022 earnings released: EPS: RON0.038 (vs RON0.016 in 2Q 2021)Second quarter 2022 results: EPS: RON0.038 (up from RON0.016 in 2Q 2021). Revenue: RON193.4m (up 16% from 2Q 2021). Net income: RON26.8m (up 145% from 2Q 2021). Profit margin: 14% (up from 6.6% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Board Change • Apr 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: RON0.14 (up from RON0.094 in FY 2020). Revenue: RON694.8m (up 25% from FY 2020). Net income: RON94.7m (up 44% from FY 2020). Profit margin: 14% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS RON0.02 (vs RON0.017 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: RON172.7m (up 26% from 3Q 2020). Net income: RON13.8m (up 20% from 3Q 2020). Profit margin: 8.0% (down from 8.4% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
Reported Earnings • Sep 03Second quarter 2021 earnings released: EPS RON0.016 (vs RON0.011 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: RON167.2m (up 30% from 2Q 2020). Net income: RON11.0m (up 41% from 2Q 2020). Profit margin: 6.6% (up from 6.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Board Change • Jul 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Francois Marchand was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • May 24Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak FoundationsThe recent earnings posted by Zentiva S.A. ( BVB:SCD ) were solid, but the stock didn't move as much as we expected. We...
Reported Earnings • May 19First quarter 2021 earnings released: EPS RON0.034 (vs RON0.049 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON163.1m (up 6.5% from 1Q 2020). Net income: RON23.6m (down 31% from 1Q 2020). Profit margin: 14% (down from 22% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 03Full year 2020 earnings released: EPS RON0.088 (vs RON0.082 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: RON602.3m (up 7.7% from FY 2019). Net income: RON61.3m (up 40% from FY 2019). Profit margin: 10% (up from 7.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
분석 기사 • Mar 01Zentiva (BVB:SCD) Has Gifted Shareholders With A Fantastic 201% Total Return On Their InvestmentPassive investing in index funds can generate returns that roughly match the overall market. But the truth is, you can...
공시 • Jan 29Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery PlatformsNanologica AB (publ) announced a collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements. The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement. Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees.
분석 기사 • Jan 25Zentiva S.A.'s (BVB:SCD) Stock Is Going Strong: Have Financials A Role To Play?Most readers would already be aware that Zentiva's (BVB:SCD) stock increased significantly by 11% over the past three...
Is New 90 Day High Low • Jan 14New 90-day high: RON2.98The company is up 6.0% from its price of RON2.82 on 16 October 2020. The Romanian market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
분석 기사 • Dec 18Zentiva S.A. (BVB:SCD) Investors Are Less Pessimistic Than ExpectedWhen close to half the companies in Romania have price-to-earnings ratios (or "P/E's") below 12x, you may consider...